Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, International Journal of Cancer, vol.13, issue.5, pp.359-86, 2015. ,
DOI : 10.1002/ijc.29210
Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients, Breast Cancer Research and Treatment, vol.100, issue.3, pp.463-73, 2013. ,
DOI : 10.1007/s10549-013-2647-2
Breast cancer prognostic classification in the molecular era: the role of histological grade, Breast Cancer Research, vol.55, issue.Suppl 2, 2010. ,
DOI : 10.1111/j.1365-2559.2009.03429.x
Molecular profiling for breast cancer: a comprehensive review, Biomark Cancer, vol.5, pp.61-70, 2013. ,
uPA/PAI-1, Oncotype DX???, MammaPrint??. Valeurs pronostique et pr??dictive pour une utilit?? clinique dans la prise en charge du cancer du sein, Bulletin du Cancer, vol.102, issue.9, pp.719-748, 2015. ,
DOI : 10.1016/j.bulcan.2015.05.003
URL : http://dx.doi.org/10.1016/j.bulcan.2015.05.003
The urokinase-type plasminogen activator system in cancer metastasis: A review, International Journal of Cancer, vol.92, issue.1, pp.1-22, 1997. ,
DOI : 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z
The Urokinase Plasminogen Activator System: Role in Malignancy, Current Pharmaceutical Design, vol.10, issue.1, pp.39-49, 2004. ,
DOI : 10.2174/1381612043453559
Cell Surface Remodeling by Plasmin: A New Function for an Old Enzyme, Journal of Biomedicine and Biotechnology, vol.41, issue.7, pp.642-59, 2012. ,
DOI : 10.1042/BJ20110129
Fibrinolysis-independent role of plasmin and its activators in the haematopoietic recovery after myeloablation, Journal of Cellular and Molecular Medicine, vol.22, issue.11-12, pp.4587-95, 2009. ,
DOI : 10.1111/j.1582-4934.2008.00521.x
Interdependence of kallikreinrelated peptidases in proteolytic networks, Biol Chem, vol.391, pp.581-588, 2010. ,
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation, Nature Genetics, vol.139, issue.4, pp.439-483, 1997. ,
DOI : 10.1038/ng1297-439
Cross-talk among proteases and matrix in the control of growth factor action, Fibrinolysis and Proteolysis, vol.11, issue.1, pp.3-9, 1997. ,
DOI : 10.1016/S0268-9499(97)80003-3
Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction, Semin Thromb Hemost, vol.39, pp.347-55, 2013. ,
uPAR: a versatile signalling orchestrator, Nature Reviews Molecular Cell Biology, vol.190, issue.12, pp.932-975, 2002. ,
DOI : 10.1038/nrm977
Dynamic Assembly of the Urokinase-type Plasminogen Activator Signaling Receptor Complex Determines the Mitogenic Activity of Urokinase-type Plasminogen Activator, Journal of Biological Chemistry, vol.280, issue.17, pp.17449-57, 2005. ,
DOI : 10.1074/jbc.M413141200
Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-??, The EMBO Journal, vol.271, issue.10, pp.1787-97, 2005. ,
DOI : 10.1038/sj.emboj.7600669
uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors, Thrombosis and Haemostasis, vol.109, issue.2, pp.309-327, 2013. ,
DOI : 10.1160/TH12-08-0546
alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)- dependent internalization of the urokinase receptor, The Journal of Cell Biology, vol.131, issue.6, pp.1609-1631, 1995. ,
DOI : 10.1083/jcb.131.6.1609
The urokinase receptor as an entertainer of signal transduction, Front Biosci, vol.14, pp.4575-87, 2009. ,
Urokinase Regulates Vitronectin Binding by Controlling Urokinase Receptor Oligomerization, Journal of Biological Chemistry, vol.277, issue.31, pp.27982-90, 2002. ,
DOI : 10.1074/jbc.M111736200
Purified alpha2-macroglobulin receptor/LDL receptor-related protein binds plasminogen activator inhibitor type-1 complex. Evidence that the alpha2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes, J Biol Chem, vol.267, pp.14543-14549, 1992. ,
Biological and clinical aspects of plasminogen activator inhibitor type 2, Blood, vol.86, pp.4007-4031, 1995. ,
Over expression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice, Cancer Res, vol.61, pp.970-976, 2002. ,
Cancer invasion and tissue remodeling-cooperation of protease systems and cell types, APMIS, vol.58, issue.1-6, pp.120-127, 1999. ,
DOI : 10.1111/j.1699-0463.1999.tb01534.x
Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation, Current Opinion in Cell Biology, vol.10, issue.5, pp.667-71, 1998. ,
DOI : 10.1016/S0955-0674(98)80044-6
Expression of the Receptor for Urokinasetype Plasminogen Activator in Normal and Neoplastic Blood Cells and Hematopoietic Tissue, American Journal of Clinical Pathology, vol.102, issue.6, pp.835-876, 1994. ,
DOI : 10.1093/ajcp/102.6.835
Blast cell surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy, Thromb Haemost, vol.81, pp.705-715, 1999. ,
Vitronectin binding to urokinase receptor in human breast cancer, Clin Cancer Res, vol.3, pp.1299-308, 1997. ,
Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: Analysis by Northern blotting andin situ hybridization, International Journal of Cancer, vol.147, issue.3, pp.286-92, 1998. ,
DOI : 10.1002/(SICI)1097-0215(19981029)78:3<286::AID-IJC4>3.0.CO;2-R
Urokinase and the Urokinase Receptor: Association With In Vitro Invasiveness of Human Bladder Cancer Cell Lines, JNCI Journal of the National Cancer Institute, vol.89, issue.10, pp.709-726, 1997. ,
DOI : 10.1093/jnci/89.10.709
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas, Am J Pathol, vol.138, pp.1059-67, 1991. ,
Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissuetype PA messenger RNAs in human hepatocellular carcinoma, Cancer Res, vol.58, pp.2234-2243, 1998. ,
A Urokinase Receptor mRNA Binding Protein???mRNA Interaction Regulates Receptor Expression and Function in Human Pleural Mesothelioma Cells, Archives of Biochemistry and Biophysics, vol.356, issue.2, pp.265-79, 1998. ,
DOI : 10.1006/abbi.1998.0789
Enhanced expression of urokinase receptor induced through the tissue factorfactor VII a pathway in human pancreatic cancer, Cancer Res, vol.58, pp.4461-4468, 1998. ,
Expression and localization of urokinase-type plasminogen activator receptor in human gliomas, Cancer Res, vol.54, pp.5016-5036, 1994. ,
Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression, Journal of Neuro-Oncology, vol.50, issue.54, pp.139-51, 1994. ,
DOI : 10.1007/BF01052889
The Biochemistry of Metastasis, Adv Clin Chem, vol.32, pp.135-66, 1996. ,
DOI : 10.1016/S0065-2423(08)60427-8
Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1, Expert Review of Molecular Diagnostics, vol.11, issue.6, pp.617-651, 2011. ,
DOI : 10.1586/erm.11.47
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice, Oncogene, vol.16, issue.24, pp.3097-104, 1998. ,
DOI : 10.1038/sj.onc.1201869
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice, International Journal of Cancer, vol.193, issue.4, pp.525-557, 2004. ,
DOI : 10.1002/ijc.20631
Human plasma fibronectin as a substrate for human urokinase, Biochemical Journal, vol.262, issue.2, pp.529-563, 1989. ,
DOI : 10.1042/bj2620529
Plasminogen Activators, Tissue Degradation, and Cancer, Adv Cancer Res, vol.44, pp.139-266, 1985. ,
DOI : 10.1016/S0065-230X(08)60028-7
Effect of plasminogen activator (urokinase), plasmin and thrombin on glycoprotein and collagenous components of basement membrane, Cancer Res, vol.41, pp.4629-4665, 1981. ,
The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin and heparanases, J Cell Biol, vol.271, pp.10079-86, 1996. ,
Proliferation of a human epidermal cell line stimulated by urokinase, FASEB J, vol.1, pp.125-133, 1987. ,
Extracellular Cleavage of the Vascular Endothelial Growth Factor 189-Amino Acid Form by Urokinase Is Required for Its Mitogenic Effect, Journal of Biological Chemistry, vol.272, issue.20, pp.13390-13396, 1997. ,
DOI : 10.1074/jbc.272.20.13390
Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA, Am J Pathol, vol.143, pp.949-58, 1993. ,
FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition, Trends in Pharmacological Sciences, vol.22, issue.4, pp.201-208, 2001. ,
DOI : 10.1016/S0165-6147(00)01676-X
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression, Journal of the National Cancer Institute, vol.92, issue.18, pp.1472-89, 2000. ,
DOI : 10.1093/jnci/92.18.1472
SCATTER-FACTOR AND SEMAPHORIN RECEPTORS: CELL SIGNALLING FOR INVASIVE GROWTH, Nature Reviews Cancer, vol.2, issue.4, pp.289-300, 2002. ,
DOI : 10.1038/nrc779
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent, The FASEB Journal, vol.16, issue.2, pp.147-54, 2002. ,
DOI : 10.1096/fj.01-0552com
Cooperativity between the Ras-ERK and Rho-Rho Kinase Pathways in Urokinase-type Plasminogen Activator-stimulated Cell Migration, Journal of Biological Chemistry, vol.277, issue.14, pp.12479-85, 2002. ,
DOI : 10.1074/jbc.M111147200
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?, The Journal of Cell Biology, vol.134, issue.6, pp.1563-71, 1996. ,
DOI : 10.1083/jcb.134.6.1563
Endogenously produced urokinase-type plasminogen activator is a major determinant of 1196 Duffy: uPA and PAI-I in Breast Cancer the basal level activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells, J Cell Sci, vol.114, pp.3387-96, 2001. ,
Reversal of the Hypomethylation Status of Urokinase (uPA) Promoter Blocks Breast Cancer Growth and Metastasis, Journal of Biological Chemistry, vol.279, issue.30, pp.31735-31779, 2004. ,
DOI : 10.1074/jbc.M401669200
The epigenetics of breast cancer, Molecular Oncology, vol.12, issue.3, pp.242-54, 2010. ,
DOI : 10.1016/j.molonc.2010.04.002
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer, Breast Cancer Research and Treatment, vol.22, issue.8670, pp.99-111, 1998. ,
DOI : 10.1023/A:1006115218786
Prognostic Value of PAI1 in Invasive Breast Cancer: Evidence That Tumor-Specific Factors Are More Important Than Genetic Variation in Regulating PAI1 Expression, Cancer Epidemiology Biomarkers & Prevention, vol.15, issue.11, pp.2107-2121, 2006. ,
DOI : 10.1158/1055-9965.EPI-06-0351
Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1, JNCI Journal of the National Cancer Institute, vol.93, issue.12, pp.913-933, 2001. ,
DOI : 10.1093/jnci/93.12.913
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node negative breast cancer, Int J Biol Markers, vol.15, pp.73-81, 2000. ,
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer, Thrombosis and Haemostasis, vol.91, pp.450-456, 2004. ,
DOI : 10.1160/TH03-12-0798
uPA/PAI-1, Oncotype DX???, MammaPrint?? Prognosis and predictive values for clinical utility in breast cancer management, Oncologie, vol.136, issue.Suppl1, pp.196-206, 2014. ,
DOI : 10.1007/s10269-014-2379-x
Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?, The Breast, vol.11, issue.5, pp.442-450, 2002. ,
DOI : 10.1054/brst.2002.0462
Rapport 2009 sur l?????tat des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX??? et MammaPrint?? dans la prise en charge du cancer du sein, Oncologie, vol.12, issue.2, pp.158-63, 2010. ,
DOI : 10.1007/s10269-009-1851-5
Editorial [Hot Topic: Targeted Therapy, Targeted Dosing and Targeted Delivery in Oncology: Where Do We Stand?], Current Topics in Medicinal Chemistry, vol.12, issue.15, p.1638, 2012. ,
DOI : 10.2174/156802612803531379
Personalized medicine in oncology: where have we come from and where are we going?, Pharmacogenomics, vol.14, issue.8, pp.931-940, 2013. ,
DOI : 10.2217/pgs.13.79
Mathematical Modeling of Tumor Growth and Metastatic Spreading: Validation in Tumor-Bearing Mice, Cancer Research, vol.74, issue.22, pp.6397-407, 2014. ,
DOI : 10.1158/0008-5472.CAN-14-0721
URL : https://hal.archives-ouvertes.fr/hal-01107681
Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach, Cancer Research, vol.76, issue.3, pp.535-582, 2016. ,
DOI : 10.1158/0008-5472.CAN-15-1389
URL : https://hal.archives-ouvertes.fr/hal-01222046
Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients, JNCI Journal of the National Cancer Institute, vol.94, issue.2, pp.116-144, 2002. ,
DOI : 10.1093/jnci/94.2.116
Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination, Journal of Clinical Oncology, vol.20, issue.4, pp.1000-1009, 2002. ,
DOI : 10.1200/JCO.2002.20.4.1000
Prognostic impact of proteolytic factors (uPA, PAI-1, cathepsins B, D, L) in primary breast cancer reflects effects of adjuvant systemic therapy, Clin Cancer Res, vol.7, pp.2757-64, 2001. ,
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer, Journal of Clinical Oncology, vol.19, issue.18, pp.3817-3844, 2001. ,
DOI : 10.1200/JCO.2001.19.18.3817
Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1, JNCI Journal of the National Cancer Institute, vol.93, issue.12, pp.913-933, 2001. ,
DOI : 10.1093/jnci/93.12.913
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up, British Journal of Cancer, vol.80, issue.3-4, pp.419-445, 1999. ,
DOI : 10.1038/sj.bjc.6690373
Clinical Application of the 70-Gene Profile: The MINDACT Trial, Journal of Clinical Oncology, vol.26, issue.5, pp.729-764, 2008. ,
DOI : 10.1200/JCO.2007.14.3222
The urokinase plasminogen activator system as a novel target for tumour therapy, Fibrinolysis and Proteolysis, vol.14, issue.2-3, pp.114-146, 2000. ,
DOI : 10.1054/fipr.2000.0079
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumors, Expert Opin Biol Ther, vol.1, issue.4, pp.683-91, 2001. ,